Moderna (MRNA) Stock Forecast & Price Target

$64.54

-2.29 (-3.43%)

(As of 02:48 PM ET)

Moderna - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 19 Analyst Ratings

Sell
2

Hold
13

Buy
4

Based on 19 Wall Street analysts who have issued ratings for Moderna in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 2 have given a sell rating, 13 have given a hold rating, and 4 have given a buy rating for MRNA.

Consensus Price Target

$100.44
57.20% Upside

According to the 19 analysts' twelve-month price targets for Moderna, the average price target is $100.44. The highest price target for MRNA is $179.00, while the lowest price target for MRNA is $48.00. The average price target represents a forecasted upside of 57.20% from the current price of $64.54.

Get the Latest News and Ratings for MRNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Moderna and its competitors.

MRNA Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)
Hold	13 Hold rating(s)	10 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)
Sell	2 Sell rating(s)	0 Sell rating(s)	2 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$100.44	$123.79	$134.02	$155.52
Forecasted Upside	57.20% Upside	59.93% Upside	15.58% Upside	50.53% Upside
Consensus Rating	Hold	Hold	Hold	Hold

$20 = Ounce of Gold? (Ad)

I've discovered a way to get exposure to MORE than an ounce of gold... for under $20. It's not bullion. It's not ETFs. And it's certainly not crypto.

Click here to find out why this is my favorite gold stock.

MRNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Moderna Stock vs. The Competition

Type	Moderna	Medical Companies	S&P 500
Consensus Rating Score	2.11	2.78	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	57.20% Upside	810.58% Upside	6.55% Upside
News Sentiment Rating	Neutral News See Recent MRNA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/19/2024	Royal Bank of Canada 4 of 5 stars	L. Issi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$75.00 ➝ $75.00	+6.47%
9/17/2024	Leerink Partners 1 of 5 stars		Lower Target	Underperform ➝ Underperform	$60.00 ➝ $48.00	-34.09%
9/16/2024	The Goldman Sachs Group 2 of 5 stars		Lower Target	Buy ➝ Buy	$178.00 ➝ $139.00	+101.19%
9/16/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$155.00 ➝ $125.00	+80.06%
9/13/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$130.00 ➝ $110.00	+62.87%
9/13/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$70.00 ➝ $60.00	-9.92%
Get the Latest News and Ratings for MRNA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.
9/13/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
9/13/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$157.00 ➝ $115.00	+65.04%
9/13/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$120.00 ➝ $65.00	-6.72%
9/13/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight	$88.00 ➝ $70.00	+0.46%
9/13/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
8/28/2024	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Liu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/28/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce ➝ Hold	$82.00	+3.82%
8/7/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Hold	$85.00 ➝ $80.00	-2.79%
6/27/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform
6/27/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	In-Line ➝ In-Line	$120.00 ➝ $120.00	-2.00%
5/7/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$143.00 ➝ $151.00	+26.77%
5/3/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$91.00 ➝ $106.00	-15.20%
9/13/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$160.00 ➝ $140.00	+26.96%
8/4/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$128.00 ➝ $123.00	+13.37%
6/26/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Upgrade
4/25/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral
2/24/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Market Perform ➝ Underperform	$111.00 ➝ $93.00	-36.98%
1/25/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$130.00 ➝ $150.00	-23.76%
1/18/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Livshits Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral	$191.00 ➝ $208.00	+4.17%
10/20/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$165.00 ➝ $145.00	+18.07%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:19 PM ET.

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 24, 2024. Please send any questions or comments about these Moderna pros and cons to contact@marketbeat.com.

Moderna
Bull Case

Here are some ways that investors could benefit from investing in Moderna, Inc.:

Moderna's stock price is currently at $65.69, potentially offering a good entry point for investors looking to buy low.
Moderna has been actively involved in developing innovative mRNA-based vaccines, positioning itself as a key player in the biotech industry.
Recent analyst reports have highlighted Moderna's potential for growth, with some maintaining buy ratings on the stock.
Moderna's strong financial position, with a market capitalization of $25.18 billion, indicates stability and growth potential.
Moderna's ongoing research and development efforts in various therapeutic areas demonstrate a commitment to long-term success.

Moderna
Bear Case

Investors should be bearish about investing in Moderna, Inc. for these reasons:

Recent price performance showing a decline in Moderna's stock price, indicating potential volatility and risk for investors.
Analyst downgrades and lowered price targets on Moderna's stock may signal concerns about future performance and market sentiment.
Increased competition in the biotech sector could impact Moderna's market share and profitability in the long run.
Moderna's negative price-to-earnings ratio of -4.19 may raise concerns about the company's profitability and valuation.
Regulatory challenges and uncertainties surrounding vaccine approvals and market acceptance could affect Moderna's revenue streams.

MRNA Forecast - Frequently Asked Questions

: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Moderna is $100.44, with a high forecast of $179.00 and a low forecast of $48.00.
: 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 2 sell ratings, 13 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
: According to analysts, Moderna's stock has a predicted upside of 55.62% based on their 12-month stock forecasts.
: Over the previous 90 days, Moderna's stock had 4 downgrades and 3 upgrades by analysts.
: Moderna has been rated by research analysts at Bank of America, Barclays, Deutsche Bank Aktiengesellschaft, Hsbc Global Res, HSBC, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Needham & Company LLC, Oppenheimer, Piper Sandler, Royal Bank of Canada, TD Cowen, and The Goldman Sachs Group in the past 90 days.
: Analysts like Moderna less than other "medical" companies. The consensus rating for Moderna is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MRNA compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

My grim warning about AI stocks (Ad)

Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.

So go here now to read my new report The Big AI Die-Up… while you still can.

This page (NASDAQ:MRNA) was last updated on 10/1/2024 by MarketBeat.com Staff

From Our Partners